OncoMatch/Clinical Trials/NCT06795022
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Is NCT06795022 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including AZD9793 Intravenous (IV) monotherapy and AZD9793 Subcutaneous (SC) monotherapy for hepatocellular carcinoma.
Treatment: AZD9793 Intravenous (IV) monotherapy · AZD9793 Subcutaneous (SC) monotherapy — This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: GPC3 expression (positive)
GPC3 positive tumour as determined by a central laboratory using an analytically validated IHC assay
Disease stage
Required: Stage IV
Confirmed advanced recurrent and/or metastatic and/or unresectable HCC, which is histopathologically proven based on the criteria established by the World Health Organization
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — HCC
Patients who have received at least one prior line of standard systemic therapy for HCC as per National Comprehensive Cancer Network or other local scientific guidelines and for which a clinical study is the best option for next treatment based on prior response and/or tolerability and/or patient/investigator decision
Lab requirements
Blood counts
Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol
Liver function
Child-Pugh Score class A
Cardiac function
Cardiac conditions as defined by the protocol
Child-Pugh Score class A. Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol. Cardiac conditions as defined by the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · La Jolla, California
- Research Site · Los Angeles, California
- Research Site · Baltimore, Maryland
- Research Site · St Louis, Missouri
- Research Site · Hackensack, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06795022 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Does this trial require GPC3?
Yes, GPC3 expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages